Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine with or without vinorelbine after dose-dense epirubicin and paclitaxel in high-risk early breast cancer
ISRCTN38983527Phase 2Completed
- Sponsor
- AGO Breast Study Group
- Start
- Oct 2003
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine, vinorelbine, epirubicin, paclitaxel, filgrastim and 1 more in breast cancer (4 arms), sponsored by AGO Breast Study Group. Primary endpoint: Toxicity. Started Oct 2003; status: completed.
02
Drugs
capecitabinevinorelbineepirubicinpaclitaxelfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN38983527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38983527.